| Name | Title | Contact Details |
|---|
OMi Cranes provides one of the few 100% turnkey solutions for your overhead lifting needs. We are a true overhead crane manufacturer, not just an assembler of others components. Whether providing a standard offering or completely customized solution, we know what works to fit your needs and budget. With over 30 years of industry experience, we provide the reliability for customers depend on. OMi Crane Systems, Inc. is a active member of Crane Manufacturers Association of America (CMAA). CMAA is an affiliate of the United States Division of Material Handling Industry (MHI). OMi Crane Systems, Inc. builds cranes to comply with OSHA standards, as well as CMAA and NEC specifications.
The first youth-powered consulting and market research agency. Join us in building confidence, fostering skills, and shaping brighter futures for all.
A private Class C Bermuda-based reinsurance company offering customized solutions to address our clients unique needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.